Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO) EBIT: E£145.8 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CAI:MCRO Macro Group Pharmaceuticals (Macro Capital) Co CAI:MCRO
38 GF Score
Price E£1.52
! 2 Warning Signs
View Full Analysis

What is Macro Group Pharmaceuticals (Macro Capital) Co EBIT?

Macro Group Pharmaceuticals (Macro Capital) Co CAI:MCRO -2.56% 38 EBIT is E£145.8 Mil as of Mar. 2026. GuruFocus rates CAI:MCRO with a GF Score™ of 38/100. The stock has 2 warning signs investors should review.

Macro Group Pharmaceuticals (Macro Capital) Co's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was E£46.9 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was E£145.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Macro Group Pharmaceuticals (Macro Capital) Co's annualized ROC % for the quarter that ended in Mar. 2026 was 23.84%. Macro Group Pharmaceuticals (Macro Capital) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 191.27%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Macro Group Pharmaceuticals (Macro Capital) Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 3.06%.

Macro Group Pharmaceuticals (Macro Capital) Co  (CAI:MCRO) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Macro Group Pharmaceuticals (Macro Capital) Co's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=173.132 * ( 1 - 24.52% )/( (552.132 + 544.145)/ 2 )
=130.6800336/548.1385
=23.84 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=778.187 - 103.898 - ( 122.157 - max(0, 503.059 - 674.72+122.157))
=552.132

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1175.035 - 155.104 - ( 475.786 - max(0, 346.188 - 1028.794+475.786))
=544.145

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Macro Group Pharmaceuticals (Macro Capital) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=187.716/( ( (76.637 + max(-78.97, 0)) + (119.651 + max(-119.54, 0)) )/ 2 )
=187.716/( ( 76.637 + 119.651 )/ 2 )
=187.716/98.144
=191.27 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(136.156 + 92.124 + -0.00099999999997635) - (103.898 + 0 + 203.351)
=-78.97

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(76.207 + 137.795 + 0) - (155.104 + 0 + 178.438)
=-119.54

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Macro Group Pharmaceuticals (Macro Capital) Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=145.752/4767.885
=3.06 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Macro Group Pharmaceuticals (Macro Capital) Co EBIT Related Terms

Macro Group Pharmaceuticals (Macro Capital) Co EBIT Historical Data

* Premium members only.

The historical data trend for Macro Group Pharmaceuticals (Macro Capital) Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Macro Group Pharmaceuticals (Macro Capital) Co EBIT Chart

Macro Group Pharmaceuticals (Macro Capital) Co Annual Data
Trend Dec20 Dec21 Dec22
EBIT
180.83 204.62 240.83

Macro Group Pharmaceuticals (Macro Capital) Co Quarterly Data
Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Jun23 Sep23 Mar24 Jun24 Sep24 Mar25 Jun25 Sep25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 38.18 32.83 55.65 43.17 46.93

CAI:MCRO vs PG, CL, KVUE: EBIT Comparison

For the Household & Personal Products subindustry, Macro Group Pharmaceuticals (Macro Capital) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Macro Group Pharmaceuticals (Macro Capital) Co EV-to-EBIT vs Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Macro Group Pharmaceuticals (Macro Capital) Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Macro Group Pharmaceuticals (Macro Capital) Co's EV-to-EBIT falls into.


CAI:MCRO
38GF Score
Macro Group Pharmaceuticals (Macro Capital) Co CAI:MCRO
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Macro Group Pharmaceuticals (Macro Capital) Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was E£145.8 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of E£145.8 Mil mean?
Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO) has a EBIT of E£145.8 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Macro Group Pharmaceuticals (Macro Capital) Co.
Is Macro Group Pharmaceuticals (Macro Capital) Co's EBIT too high?
Macro Group Pharmaceuticals (Macro Capital) Co's current EBIT is E£145.8 Mil. Overall, Macro Group Pharmaceuticals (Macro Capital) Co has a GF Score™ of 38/100, reflecting its overall financial health beyond just this single metric.
How does Macro Group Pharmaceuticals (Macro Capital) Co's EBIT compare to PG and CL?
Macro Group Pharmaceuticals (Macro Capital) Co's EBIT of E£145.8 Mil can be compared against companies in the Consumer Packaged Goods industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Consumer Packaged Goods company?
A good EBIT depends on the Consumer Packaged Goods industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Macro Group Pharmaceuticals (Macro Capital) Co. Macro Group Pharmaceuticals (Macro Capital) Co's current EBIT is E£145.8 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macro Group Pharmaceuticals (Macro Capital) Co stock overvalued right now?
Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO) has a current EBIT of E£145.8 Mil. The current EBIT is E£145.8 Mil. Macro Group Pharmaceuticals (Macro Capital) Co's overall GF Score™ is 38/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Macro Group Pharmaceuticals (Macro Capital) Co (CAI:MCRO), the current EBIT is E£145.8 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Macro Group Pharmaceuticals (Macro Capital) Co Business Description

Address 83, Al Moltaka Al Arabi, Sheraton, Cairo, EGY
Macro Group Pharmaceuticals (Macro Capital) Co is principally engaged in the manufacture and sale of cosmeceutical and ventured into nutraceutical products.
38GF Score

Get the complete analysis for CAI:MCRO

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

E£1.52
Price